Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV004704831 | SCV001157173 | likely benign | not provided | 2024-09-25 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001000389 | SCV001362677 | likely benign | not specified | 2019-08-30 | criteria provided, single submitter | clinical testing | |
Johns Hopkins Genomics, |
RCV001250547 | SCV001425367 | likely benign | Cystic fibrosis | 2020-05-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001250547 | SCV001683299 | likely benign | Cystic fibrosis | 2024-09-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001250547 | SCV002610188 | likely benign | Cystic fibrosis | 2016-10-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Breakthrough Genomics, |
RCV004704831 | SCV005221520 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001250547 | SCV001461256 | likely benign | Cystic fibrosis | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004537228 | SCV004726088 | likely benign | CFTR-related disorder | 2023-12-11 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |